A Phase 1 interventional study of SHR-4658 Injection. and SHR-4658 Placebo Injection in Heart Failure, sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-17.
Sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Heart Failure by Jiangsu HengRui Medicine Co., Ltd. — 5 open to participants now, 7 under way, none of them phase 3. Heart Failure · Jiangsu HengRui Medicine Co., Ltd..
Among the 10 studies in Heart Failure by Jiangsu HengRui Medicine Co., Ltd., this one is the 7th largest by planned enrollment, is one of 3 that started in 2025, is one of 6 in phase 1, and was the 5th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.
Browse Heart Failure studies →5 of the 10 studies in Heart Failure by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
Chengdu Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 40+
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 48 is below the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 69 across the 10 interventional studies. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Beijing Suncadia Pharmaceuticals Co., Ltd, one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Beijing Suncadia Pharmaceuticals Co., Ltd is the lead sponsor of 25 studies on the registry; 9 are open to participants now.
2 of the studies in Heart Failure by Jiangsu HengRui Medicine Co., Ltd. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07551167Chengdu Suncadia Medicine Co., Ltd.A Clinical Study of HRS-5765 in Healthy Participants | 2026-12 |
| NCT07269717Shandong Suncadia Medicine Co., Ltd.A Phase II Clinical Trial of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Heart Failure by Jiangsu HengRui Medicine Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and immunogenicity of single subcutaneous injection of SHR-4658 in healthy volunteers and volunteers with elevated blood pressure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SHR-4658 Injection.
Drug: SHR-4658 Placebo Injection
SHR-4658 injection.
SHR-4658 placebo injection.
Adverse events (AEs)
Time frame: Approximately 16 weeks.
Area under the concentration-time curve from time 0 to the last time point (AUC0-last)
Time frame: Approximately 16 weeks.
Area under the concentration-time curve from time 0 to infinity (AUC0-inf)
Time frame: Approximately 16 weeks.
Maximum observed concentration (Cmax)
Time frame: Approximately 16 weeks.
Time to maximum observed concentration (Tmax)
Time frame: Approximately 16 weeks.
Apparent clearance (CL/F)
Time frame: Approximately 16 weeks.
Apparent volume of distribution (Vd/F)
Time frame: Approximately 16 weeks.
Terminal elimination half-life (t1/2)
Time frame: Approximately 16 weeks.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Nov 2025; primary completion for Jun 2026, 7 months later.
Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's planned 7 months is close to that.
Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Suncadia Pharmaceuticals Co., Ltd →